CoChat

Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

The present studies were conducted to determine if increasing central levels of the neurotrophic factor insulin-like growth factor-1 (IGF-I) either directly or indirectly produces anxiolytic and antidepressant-like effects in the mouse. Central levels of IGF-I can be increased directly, by administering IGF-I, or indirectly by blocking the insulin-like growth factor binding proteins (IGFBPs). The IGFBP family has the unique ability to regulate IGF-I levels by sequestering IGF-I into an inactive complex. Therefore, an IGFBP inhibitor increases the level of IGF-I available to bind to its receptor. Intracerebroventricular (icv) administration of the nonspecific IGFBP inhibitor NBI-31772 (10-30 microg) increases the number of punished crossings in the four-plate test and NBI-31772 (0.3-10 microg) increases time spent in the open quadrant of the elevated zero maze (EZM), indicative of anxiolytic-like effects. NBI-31772 (3-30 microg) also decreases immobility time in the tail suspension test, indicative of antidepressant-like effects. Similarly, icv administration of IGF-I (0.1 microg) produces anxiolytic-like effects in the four-plate test and IGF-1 (0.3-1 microg) produces anxiolytic-like effects in the EZM. IGF-I (10 microg) also produces antidepressant-like effects in the tail suspension test. Coadministration of the IGF-I receptor antagonist JB1 with NBI-31772 or IGF-I blocks the anxiolytic-like and antidepressant-like effects of these compounds. These results suggest that NBI-…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1301358

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 113

Metadata

Authors
Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S.
Affiliations
  • Wyeth (US)
  • University of Pennsylvania (US)
Corresponding author
Malberg, Jessica E
Venue
Neuropsychopharmacology
Published
2007-03-07
Volume
32
Issue
11
Pages
2360-2368
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W1977606691
Cited by
101
References
47
Citations by year
2026: 2 · 2025: 4 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 4 · 2013: 9 · 2012: 3
FWCI
6.82
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (MH 72832, U01MH072832)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
insulin-like growth factor I, anxiolytic effects, antidepressant effects, IGF-1 receptor, neurotrophic factors, depression, anxiety, intracerebroventricular administration, elevated zero maze, tail suspension test, four-plate test
MeSH terms
Analysis of Variance, Animals, Antidepressive Agents, Anxiety, Avoidance Learning, Behavior, Animal, Catechols, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors, Gene Expression Regulation, Injections, Intraventricular, Insulin-Like Growth Factor I, Isoquinolines, Male, Motor Activity, Insulin-Like Growth Factor Binding Proteins, Hindlimb Suspension, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects. https://app.cochat.ai/papers/10.1038/sj.npp.1301358
The paper
Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S. (2007). Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1301358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.